Information Provided By: 
Fly News Breaks for January 18, 2017
LLY, CLCD
Jan 18, 2017 | 12:21 EDT
After CoLucid Pharmaceuticals (CLCD) announced an agreement to be acquired by Eli Lilly (LLY)for $46.50 per share, or approximately $960M, BTIG analyst Robert Hazlett said he thinks there is still potential for additional interest given the strength of the initial Phase 3 data for Lasmiditan. Hazlett keeps his Buy rating on CoLucid shares, but lowered his price target to $52 from $58.
News For CLCD;LLY From the Last 2 Days
There are no results for your query CLCD;LLY
